iBio, Inc. (IBIO) analyst actions
Rating and price-target actions on IBIO in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the IBIO overview →
1 measured IBIO analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment | Press release | -4.17% | -8.96% |
Keep exploring
More IBIO: earnings → · SEC filings → · IBIO overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Relmada Therapeutics, Inc. (RLMD) | 265 | -0.01% | 44% |
| HUTCHMED (China) Limited - American Depositary Shares (HCM) | 263 | 0.00% | 47% |
| NOVUS THERAPEUTICS (NVUS) | 263 | -0.14% | 40% |
| Haemonetics Corporation (HAE) | 261 | -0.07% | 44% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.